Individualizing Treatment with Current and Emerging Therapies

As the number of new and emerging treatment options for patients with PsA continues to expand, dermatology and rheumatology healthcare providers are challenged with keeping pace with the continually escalating amount of clinical trial data for PsA agents that have been recently approved or are in the late-stages of development. This activity will provide an expert-guided overview of the safe and effective use of novel and investigational PsA agents, as well as practice-based learning, to help practitioners better develop effective, individualized PsA treatment plans.


The goal of this activity is to provide dermatology and rheumatology clinicians timely and applicable clinical practice data, as well as expert recommendations, to better improve the understanding and care of patients with PsA with recently approved and late-stage treatment options.


This activity has been designed for members of dermatology and rheumatology healthcare provider teams in practices that care for patients who are at-risk for psoriatic arthritis (PsA). No prerequisites required.


Upon completion of this activity, participants will be better able to:

  1. DEVELOP effective treatment plans for patients with PsA based on their individual needs.
  2. EVALUATE the use of novel and emerging agents in patients with PsA, based on the most current safety and efficacy data.


M. Elaine Husni, MD, MPH (Chair)
Vice Chair
Department of Rheumatic and Immunologic Diseases
Director of the Arthritis and Musculoskeletal Center
Cleveland Clinic
Assistant Professor
Cleveland Clinic Lerner
College of Medicine
Case Western Reserve University
Cleveland, Ohio

Lihi Eder, MD, PhD
Scientist, Women’s College Research Institute
Staff Rheumatologist
Division of Rheumatology
Women’s College Hospital
Assistant Professor
Department of Medicine
University of Toronto
Toronto, Ontario, Canada

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Relationship Identified With:

M. Elaine Husni, MD, MPH (Chair)

Consultant/Advisor: AbbVie Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, UCB Inc.

Royalties/Patents: PASE Questionnaire

Lihi Eder, MD, PhD

Speakers’ Bureau: AbbVie Inc, Amgen Inc, Celgene Corporation, Janssen Pharmaceuticals, Inc.

Consultant/Advisor: AbbVie Inc, Celgene Corporation.

Grant/Research Support: AbbVie Inc.

Non-faculty: Daniel Guinee; Nicolle Rochino, PharmD; Sandy Breslow; Leah Johnson; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Pfizer Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and ASiM.


CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and ASiM. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For all CME inquiries or special needs, please contact

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, ASiM, and Pfizer Inc do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 0.50 AMA PRA Category 1 Credit(s)™
  • 0.50 Non-physician

Accreditation Period

Course opens: 
Course expires: 
Please login or register to take this course.